Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + pemetrexed + bevacizumab in first-line driver-gene-negative advanced non-squamous NSCLC
ChiCTR2000041218Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) and bronchial carcinoma, sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Started Aug 2020; status: recruiting.
02
Drugs
camrelizumabpemetrexedbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2000041218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041218.